The Biostatistics Center (BSC) based at the George Washington University Milken Institute School of Public Health served as the coordinating center for a new study examining disease progression in youth and adults with Type 2 diabetes, which was conducted at eight study sites nationwide.
The Biostatistics Center managed numerous aspects of the study, including working with the researchers on the study design, developing the operation manuals; designing and implementing the data collection systems; and analyzing data for the study.
The study found adults with Type 2 diabetes fared better during medical treatment but worsened after treatment ended, while youth on the same treatment continued to worsen both during and after. The research was published June 9 in Diabetes and Diabetes Care.
The findings of the new study were compared to those from the 2018 RISE Pediatric Medication Study, which showed that beta cell function declined in two youth treatment groups during active treatment, and worsened after treatment ended.
“Together, the RISE medication studies show that these treatments for type 2 diabetes do not make lasting changes to the beta cells,” says Ms. Sharon Edelstein, ScM, principal investigator of the BSC coordinating center. “In RISE adults, the treatment options were effective while people were actively taking them, but the effectiveness disappeared once the medications were stopped. In order to maintain benefits to the beta cells, individuals must remain on treatment.”Friday Letter Submission, Publish on June 14